{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bupropion+Extended+Release+Oral+Tablet",
    "query": {
      "intervention": "Bupropion Extended Release Oral Tablet"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 20,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bupropion+Extended+Release+Oral+Tablet&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T14:36:56.161Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01046214",
      "title": "Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Bupropion HCl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Pharmaceuticals USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "25 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2010-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-11-20",
      "last_synced_at": "2026-09-26T14:36:56.161Z",
      "location_count": 2,
      "location_summary": "Culver City, California • Glendale, California",
      "locations": [
        {
          "city": "Culver City",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01046214"
    },
    {
      "nct_id": "NCT04553263",
      "title": "Relapse Prevention in Stimulant Use Disorder",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Stimulant Use",
        "Relapse",
        "Cognitive Function",
        "ADHD"
      ],
      "interventions": [
        {
          "name": "Contrave 8Mg-90Mg Extended-Release Tablet",
          "type": "DRUG"
        },
        {
          "name": "Bupropion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2023-06-11",
      "completion_date": "2025-01-11",
      "has_results": false,
      "last_update_posted_date": "2023-09-22",
      "last_synced_at": "2026-09-26T14:36:56.161Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04553263"
    },
    {
      "nct_id": "NCT06090461",
      "title": "Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Obesity"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Currax Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31889,
      "start_date": "2014-09",
      "completion_date": "2022-12",
      "has_results": true,
      "last_update_posted_date": "2025-06-25",
      "last_synced_at": "2026-09-26T14:36:56.161Z",
      "location_count": 1,
      "location_summary": "Brentwood, Tennessee",
      "locations": [
        {
          "city": "Brentwood",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06090461"
    },
    {
      "nct_id": "NCT06609343",
      "title": "Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "End Stage Renal Disease",
        "Fatigue"
      ],
      "interventions": [
        {
          "name": "Bupropion Hydrochloride 150 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "25 Years to 74 Years"
      },
      "enrollment_count": 16,
      "start_date": "2026-08-24",
      "completion_date": "2027-01-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-09-26T14:36:56.161Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06609343"
    },
    {
      "nct_id": "NCT00439868",
      "title": "A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular Pressure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "WellbutrinXL",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 33,
      "start_date": "2007-02-16",
      "completion_date": "2007-06-08",
      "has_results": false,
      "last_update_posted_date": "2017-08-10",
      "last_synced_at": "2026-09-26T14:36:56.161Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00439868"
    },
    {
      "nct_id": "NCT00865371",
      "title": "A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fed Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Abrika Bupropion 150 mg Extended-Released Tablet",
          "type": "DRUG"
        },
        {
          "name": "Wellbutrin SR® 150 mg Extended-Release Tablet, single dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 26,
      "start_date": "2004-09",
      "completion_date": "2004-09",
      "has_results": false,
      "last_update_posted_date": "2010-08-16",
      "last_synced_at": "2026-09-26T14:36:56.161Z",
      "location_count": 1,
      "location_summary": "Fort Myers, Florida",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00865371"
    },
    {
      "nct_id": "NCT06233799",
      "title": "Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Methamphetamine-dependence",
        "Methamphetamine Abuse"
      ],
      "interventions": [
        {
          "name": "extended-release naltrexone (XR-NTX)",
          "type": "DRUG"
        },
        {
          "name": "extended release bupropion (BUP-XL) tablets (BUP-XL)",
          "type": "DRUG"
        },
        {
          "name": "iPLB",
          "type": "DRUG"
        },
        {
          "name": "oPLB",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute on Drug Abuse (NIDA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 360,
      "start_date": "2024-07-01",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-09-26T14:36:56.161Z",
      "location_count": 11,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • San Diego, California + 8 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06233799"
    },
    {
      "nct_id": "NCT00865410",
      "title": "A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Abrika Bupropion 150 mg Extended-Released Tablet",
          "type": "DRUG"
        },
        {
          "name": "Wellbutrin SR® 150 mg Extended-Release Tablet, single dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 26,
      "start_date": "2004-08",
      "completion_date": "2004-09",
      "has_results": false,
      "last_update_posted_date": "2010-08-16",
      "last_synced_at": "2026-09-26T14:36:56.161Z",
      "location_count": 1,
      "location_summary": "Fort Myers, Florida",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00865410"
    },
    {
      "nct_id": "NCT02735603",
      "title": "Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Heart Repolarization"
      ],
      "interventions": [
        {
          "name": "Naltrexone HCl/bupropion HCl",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Orexigen Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 84,
      "start_date": "2016-04",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2016-11-01",
      "last_synced_at": "2026-09-26T14:36:56.161Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02735603"
    },
    {
      "nct_id": "NCT02400346",
      "title": "Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Major Depression Disorder"
      ],
      "interventions": [
        {
          "name": "Adjunct brexpiprazole",
          "type": "DRUG"
        },
        {
          "name": "ADT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lundbeck A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 132,
      "start_date": "2015-03",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2017-08-10",
      "last_synced_at": "2026-09-26T14:36:56.161Z",
      "location_count": 13,
      "location_summary": "Arcadia, California • Miami, Florida • Orlando, Florida + 9 more",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Smyrna",
          "state": "Georgia"
        },
        {
          "city": "O'Fallon",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02400346"
    }
  ]
}